Navigation Links
Boehringer Ingelheim Presents Progression-Free Survival Data for Investigational Afatinib and Nintedanib in Advanced NSCLC
Date:5/15/2013

tyrosine kinases shown to aid in the regulation of angiogenesis: fibroblast growth factor (FGF) receptor, platelet-derived growth factor (PDGF) receptor, and vascular endothelial growth factor (VEGF) receptor.

Nintedanib is being evaluated in various solid tumors – including advanced NSCLC, ovarian cancer, liver cancer (hepatic cell carcinoma), kidney cancer (renal cell carcinoma) and colorectal cancer. The advanced NSCLC and ovarian cancer clinical trials are in Phase III development. Nintedanib is also being investigated in Phase III trials for the treatment of Idiopathic Pulmonary Fibrosis (IPF), a progressive and severely debilitating lung disease.

Nintedanib is not approved by the FDA; its safety and efficacy have not been established. 

About Boehringer Ingelheim in Oncology

Building on scientific expertise and excellence in the fields of pulmonary and cardiovascular medicine, metabolic disease, neurology, virology and immunology, Boehringer Ingelheim has embarked on a major research program to discover and develop innovative cancer treatments.  Working in close collaboration with the international scientific community and a number of the world's leading cancer centers, Boehringer Ingelheim's commitment to oncology is underpinned by using advances in science to develop a range of targeted therapies for various solid tumors and hematological cancers. The current focus of late-stage research includes compounds in three areas: signal transduction inhibition, angiogenesis inhibition and cell-cycle kinase inhibition. The company is also evaluating a robust and growing pipeline of early-stage oncology compounds in areas including growth/survival signaling, immunotherapy and epigenetics.

For information about participating in a Boehringer Ingelheim clinical trial, please visit www.bicancertrials.com or call 1.866.725.7110. Healthcare providers interested in learning more
'/>"/>

SOURCE Boehringer Ingelheim Pharmaceuticals, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9

Related medicine technology :

1. Boehringer Ingelheim Announces Launch of GLORIA™-AF Registry in Newly-Diagnosed Patients with Non-Valvular Atrial Fibrillation
2. New Data to be Presented at the Annual American Thoracic Society International Conference Demonstrates Depth of Boehringer Ingelheim Respiratory Research Pipeline
3. Boehringer Ingelheim to present pivotal Phase III results for afatinib in first-line treatment of EGFR mutation-positive NSCLC at ASCO 2012
4. Results of Phase II Study of Boehringer Ingelheims Investigational Bronchodilator for COPD Presented at 2012 ATS International Conference
5. Boehringer Ingelheim Presents First Data for Tiotropium in Adolescents with Moderate Persistent Asthma
6. Lilly and Boehringer Ingelheim Present Data at the 72nd American Diabetes Association Scientific Sessions® from Phase II Studies Comparing Investigational Novel Basal Insulin to Insulin Glargine
7. Boehringer Ingelheim and Lilly introduce the My Well Planner Lifestyle Improvement Program for Adults with Type 2 Diabetes
8. Boehringer Ingelheim announces afatinib expanded access program (EAP) for patients with EGFR mutation-positive advanced NSCLC
9. Whistleblowers extraordinary efforts helped win $95 million settlement with Boehringer Ingelheim
10. Phase 2b Data of Boehringer Ingelheims Interferon-Free Hepatitis C Treatment Show Viral Cure Achieved in Up to 85% of Treatment-Naive Patients
11. Boehringer Ingelheim Announces Equine Research Awards
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/23/2014)... , Sept. 23, 2014 Cerevast Therapeutics ... today the outcome of the first interim analysis ... the Company,s proprietary Clotbust ER TM ... ischemic stroke. The independent Data Safety Monitoring Board ... planned. "Clearing the pre-specified futility threshold ...
(Date:9/23/2014)... therapy recently began in the Czech Republic for ... the United States draws to a close today ... days to live now looks forward to his first day of kindergarten. ... complained of a headache in June, it was the first ... 23, when he completes proton radiation therapy for a brain ...
(Date:9/23/2014)... Sept. 23, 2014 CASI Pharmaceuticals, Inc. (Nasdaq: ... the acquisition, development and commercialization of innovative therapeutics addressing ... market with a primary focus on China ... Shrotriya , MD, Chairman and Chief Executive Officer of ... appointment was made in connection with the recently announced ...
Breaking Medicine Technology:Cerevast Therapeutics Announces Outcome of First Interim Analysis of Phase 3 CLOTBUSTER Trial for the Treatment of Acute Ischemic Stroke 2Cerevast Therapeutics Announces Outcome of First Interim Analysis of Phase 3 CLOTBUSTER Trial for the Treatment of Acute Ischemic Stroke 35-Year-Old Brain Cancer Patient Completes Proton Therapy, Awaits Kindergarten 25-Year-Old Brain Cancer Patient Completes Proton Therapy, Awaits Kindergarten 35-Year-Old Brain Cancer Patient Completes Proton Therapy, Awaits Kindergarten 4CASI Pharmaceuticals Announces Appointment Of Rajesh C. Shrotriya, MD To The Board Of Directors 2CASI Pharmaceuticals Announces Appointment Of Rajesh C. Shrotriya, MD To The Board Of Directors 3CASI Pharmaceuticals Announces Appointment Of Rajesh C. Shrotriya, MD To The Board Of Directors 4
... SAN DIEGO, May 7, 2012  Halozyme Therapeutics, Inc. (NASDAQ: ... the quarter ended March 31, 2012. (Logo:  ... milestone in the first quarter with the European regulatory ... Roche," said Gregory I. Frost, Ph.D., President and Chief ...
... May 7, 2012 The National Council on ... customized, online educational modules to promote safe use ... in America, acetaminophen, is found in more than ... relievers, fever reducers, and sleep aids as well ...
Cached Medicine Technology:Halozyme Reports First Quarter 2012 Financial Results 2Halozyme Reports First Quarter 2012 Financial Results 3Halozyme Reports First Quarter 2012 Financial Results 4Halozyme Reports First Quarter 2012 Financial Results 5Halozyme Reports First Quarter 2012 Financial Results 6Safe Use of Acetaminophen 2Safe Use of Acetaminophen 3Safe Use of Acetaminophen 4
(Date:9/23/2014)... 2014 What: Rutgers Presbyterian Church, ... Side that embodies the inclusion and diversity of ... and the Ecological Crisis, a public lecture led ... Emerita of Old Testament at Louisville Presbyterian Seminary. ... that lends insight into current ecological problems, including ...
(Date:9/23/2014)... benefits of preventing a reduction in the rates ... today by the American College of Physicians (ACP). ... Medicaid Primary Care Pay Parity Program: Unless Congress ... Care Will Expire," explains why it is critical ... pediatricians (and their related subspecialists), family physicians, and ...
(Date:9/23/2014)... Singapore (PRWEB) September 23, 2014 ... aesthetic clinics in Singapore and Malaysia providing advanced ... revolutionary BB powder to its impressive skin care ... strengthen the skin’s defences against the evil forces ... a healthy glow simultaneously, this new addition is ...
(Date:9/23/2014)... TUESDAY, Sept. 23, 2014 (HealthDay News) -- The ... million in additional funding in scientific trials to ... and clinical studies. The supplemental monies were ... fields, including basic immunology, cardiovascular physiology, neural circuitry, ... Sept. 23. "This funding strategy demonstrates our ...
(Date:9/23/2014)... Karl Klose, professor of biology and a researcher in ... teamed up with researchers at Ruhr University in Bochum, ... Their findings were released this week in an article ... of Sciences . , Cholera is an acute infection ... contaminated with the bacterium Vibrio cholerae . An ...
Breaking Medicine News(10 mins):Health News:Inhabiting Eden: Christians, Scripture, and the Ecological Crisis – Public Lecture to Discuss Faith-Based Environmentalism 2Health News:Unless Congress acts, patients may soon lose access to primary care 2Health News:Unless Congress acts, patients may soon lose access to primary care 3Health News:The Sloane Clinic™ introduces a revolutionary BB powder to its impressive skin care repertoire 2Health News:The Sloane Clinic™ introduces a revolutionary BB powder to its impressive skin care repertoire 3Health News:The Sloane Clinic™ introduces a revolutionary BB powder to its impressive skin care repertoire 4Health News:NIH Adds $10M to Encourage Gender Balance in Clinical Trials 2Health News:UTSA microbiologists discover regulatory thermometer that controls cholera 2
... at the University of Cambridge claim to have identified four ... ,They made this breakthrough by using the new trawling ... simultaneously instead of one by one. ,They believe ... 12 to 15 years, in which the inherited risk of ...
... by a team of researchers led by Dr Peter Burney ... ,As part of the study, researchers analysed schoolchildren who were ... ,Researchers asked their parents about their kids fruit consumption ... study found that although there was no connection between apple ...
... has been reduced to begging for survival in Orissa after villagers ... can be passed on by social contact. ,And ... Sukanti (name changed), only 30 years of age, and her younger ... Cuttack district, 50 km from here. ,Life became hell ...
... more likely to later develop Alzheimer's disease than people ... study published in the May 29, 2007, issue of ... Neurology. ,The study, which is part of ... with an average age of 79. Blood tests determined ...
... public health problem in many developing countries, frequently ... survive. Often undiagnosed or untreated, syphilis is passed from ... in prenatal programs to prevent the spread of HIV. ... College and the Groupe Haitien d'Etude du Sarcome de ...
... change policy, ministers from Asia - including India's - met ... for talks on world crises. ,The two-day Asia-Europe ... division between European countries seeking deep cuts in world carbon-dioxide ... global warming. ASEM is held every two years. India, Pakistan ...
Cached Medicine News:Health News:Scientists Identify Four Genes That Raise the Risk of Breast Cancer 2Health News:Apple Juice may Help to Keep Childhood Asthma at Bay 2Health News:Rapid Syphilis Could Prevent Congenital Disease and Stillbirths in Haiti 2Health News:Rapid Syphilis Could Prevent Congenital Disease and Stillbirths in Haiti 3Health News:EU Pushes Asian Nations on Climate Change Goals 2
... manufactures slides that are compatible with multichannel ... the number of pipetting steps required to ... on the slides. Ask Immuno Concepts for ... slides. These slide formats are noted with ...
... ANA uses a patented HEp-2 cell line ... the sensitivity to SS-A/Ro autoantibodies, without affecting ... studies have been published worldwide on the ... to SS-A/Ro autoantibodies when used in place ...
... and ENA assays can be used ... antinuclear antibodies, which are associated with ... Systemic lupus erythematosus (Lupus), Sjgren's syndrome, ... sclerosis, scleroderma, polymyositis, dermatomyositis, and Raynaud's ...
... assays can be used to screen ... which are associated with various systemic ... erythematosus (Lupus), Sjgren's syndrome, mixed connective ... polymyositis, dermatomyositis, and Raynaud's phenomenon. They ...
Medicine Products: